Tenpoint Therapeutics, a clinical-stage cell therapy targeting unmet needs in ocular diseases, has added Kali Stasi, M.D., Ph.D., as its Senior Vice President of Clinical Development.

Previously, Kali served as a Translational Medicine Director at the Novartis Institutes for Biomedical Research, where she served as a clinical development leader for cell & gene therapy products programs pertaining to front- and back-of-the-eye indications. Prior to Novartis, Kali served as a professor & researcher at the University of Pennsylvania.

Kali Stasi earned her M.D. and Ph.D from the University of Patras, in Greece. She completed residencies at The Massachusetts Eye & Ear Infirmary, Mount Sinai Hospital, Johns Hopkins Hospital, and the Albert Einstein College of Medicine.